Fig 1: A. Plasma His-ALT1 activities of vehicle control and Sotuletinib-treated rats (day 7 to 9). Rats were treated once daily at a dose level of 150 mg/kg for 9 days (mean ± SEM, n = 5 per timepoint up to 42 h in order to respect blood volume withdrawal in live animals; n = 10 for 50 h after His-ALT1 injection). His-tagged ALT1 i.v. injection (0.2 mg/kg) was on day 7 of Sotuletinib treatment. B. Endogenous ALT values at predose, day 7 and 9 of Sotuletinib treatment, before injection of His-tag ALT1. **p < 0.01, and ****p < 0.0001: significant difference compared to respective vehicle control using the Sidak-Bonferroni multiple t tests (α = 0.05).
Fig 2: A: Kinetic of ALT elevation upon Sotuletinib treatment and reversibility upon compound withdrawal. Open circle: continuous Sotuletinib treatment at 150 mg/kg/day (12 animals); black triangles: treatment at the same dose up to day 16 and then compound withdrawal (12 animals); black circles: vehicle controls (8 animals). Bars: standard deviation. B: miR-122 in control and treated animals at day 3, 8 and 14; black circles: vehicle controls, Open circle: Sotuletinib treatment.
Supplier Page from Creative BioMart for Recombinant Rat Gpt, His tagged